Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.38 |
| ▸ | KCNA6 | P17658 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940426 | 0.79 | BLM (0.50) | DAOGRIN1TTREIF4A3 | |
| SCHEMBL11607578 | 0.79 | DAO (0.39) | DAOKCNA6KCNA3KCNA4KCNA5 | |
| SCHEMBL8278471 | 0.77 | TYMP (0.36) | DAOKCNA6KCNA3KCNA4KCNA5 | |
| Hydrochloric Acid SCHEMBL11607586 | 0.77 | GRIN1 (0.48) | DAOGRIN1TTREIF4A3 | |
| SCHEMBL24112866 | 0.77 | ALOX15 (0.51) | DAOKCNA6KCNA3KCNA4KCNA5 | |
| SCHEMBL3022139 | 0.77 | TTR (0.38) | DAOCCNCCDK8GRIN1TTR | |
| SCHEMBL11813309 | 0.74 | DAO (0.36) | DAOKCNA6KCNA3KCNA4KCNA5 | |
| SCHEMBL3035325 | 0.72 | CYP1A2 (0.40) | — | |
| SCHEMBL24740419 | 0.72 | ALOX15 (0.55) | DAOKCNA6KCNA3KCNA4KCNA5 | |
| SCHEMBL24019830 | 0.72 | ALOX15 (0.55) | DAOKCNA6KCNA3KCNA4KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297830-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF BACTERIAL INFECTIOUS DISEASES | GALAPAGOS NV (BE) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297830-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF BACTERIAL INFECTIOUS DISEASES | POLR2E, POLB, POLI | DAO 1152/4885KCNA6 4369/4885KCNA3 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.